This article was originally published here
Hosp Pract (1995). 2020 Dec 11. doi: 10.1080/21548331.2020.1863052. Online ahead of print.
ABSTRACT
BACKGROUND Hospitalists at our institution have taken on most non-intensive care unit (ICU) coronavirus disease 2019 (COVID-19) care. Based on sparse research, our institution developed a protocol for ordering labs for this patient population, including routine admission labs in addition to eight COVID-19 specific daily labs. The study goal is to determine if COVID-19 specific admission labs have any prognostic value beyond that provided by routine admission labs and vitals, and costs of labs with no prognostic value. METHODS We retrospectively reviewed adult patients admitted with COVID-19 from 3/2020 to 7/2020. Outcomes were mortality, ICU stay and length of hospitalization. Multivariable logistic and linear regression were used to determine if COVID-19 specific admission labs have any prognostic value beyond that provided by vitals and routine admission labs. COVID-19 specific labs were d-Dimer, fibrinogen, ferritin, LDH, CK, pro-BNP, troponin and CRP. Multivariable models included all routine admission labs and vitals. COVID-19 specific admission labs were included in the multivariable models if the p-value was <0.05 in the univariable analysis. RESULTS 331 patients met study criteria, inpatient mortality was 13.0%, 52.4% of patients required ICU stays and the average length of hospitalization was 8.9 days. COVID-19 specific labs showed no additional prognostic value for mortality. CRP, LDH and d-Dimer provided additional prognostic information for ICU stay. CRP≥100mg/dL and LDH≥900U/L were associated with increased length of hospitalization. CONCLUSION Only 3 of 8 admission COVID-19 specific labs recommended by our institution’s protocol had additional prognostic value beyond that provided by routine labs and vitals. The total cost of non-prognostic COVID-19 specific labs during the study period was $75,874.
PMID:33306437 | DOI:10.1080/21548331.2020.1863052
